ImmunityBio (IBRX) Proxy filing summary

Executive summary

• Achieved commercial scale and multiple international approvals for ANKTIVA, with 2025 net product revenue of $113 million, a 700% increase over the prior year, and unit sales up 750%.

• Expanded global regulatory approvals, including the UK, EU, and China for new indications, and advanced clinical trials in multiple cancer types.

• Raised over $400 million in capital and accelerated enrollment in key clinical trials.

• Implemented a permanent J-code for ANKTIVA, simplifying reimbursement and accelerating adoption.

• Addressed the BCG shortage through an FDA-authorized Expanded Access Program.

Voting matters and shareholder proposals

• Stockholders will vote to elect nine directors to serve until the 2027 annual meeting.

• Proposal to ratify Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

• Board recommends voting FOR all director nominees and FOR the auditor ratification.

Board of directors and corporate governance

• Board consists of nine members, six of whom are independent under Nasdaq rules.

• Dr. Soon-Shiong serves as Executive Chairman; Ms. Cohen is Lead Independent Director.

• Board committees include Audit, Compensation, Nominating and Corporate Governance, and Related Party Transaction Committees.

• Controlled company exemption applies due to majority ownership by Dr. Soon-Shiong and affiliates.

• Board and committees held regular meetings, with all directors attending at least 75% of meetings.